People with HIV (PWH) have a high risk of coronary artery disease (CAD). Cytomegalovirus (CMV) co-infection is very common in PWH, but little is known about its association with CAD. We aimed to investigate if CMV IgG serostatus and concentrations are associated with CAD in PWH. From the Copenhagen Comorbidity in HIV Infection (COCOMO) Study we included PWH with coronary CT angiography (CCTA) and quantitative CMV IgG concentration measurements. We measured the stenosis grades and plaque volumes in the coronary vessels. Using multivariable regressions adjusted for traditional CAD risk factors, we investigated if CMV IgG serostatus and concentrations were associated with any atherosclerosis, obstructive CAD, or plaque volumes. We included 620 PWH of whom 586 had positive CMV serostatus, which was not associated with any atherosclerosis, obstructive CAD, or plaque volumes. A doubling of CMV IgG concentrations was associated with any atherosclerosis (OR 1.21 [95% CI: 1.06–1.39]), obstructive CAD (OR 1.31 [95% CI: 1.07–1.59]), and higher total plaque volume (1.56 [95% CI: 1.21–2.01] fold increase), but the association did not remain significant after adjustment for traditional CAD risk factors. This indicates that CMV IgG serostatus and concentrations are not independently associated with prevalent CAD in PWH.
Background: Despite pre-transplantation vaccination against invasive pneumococcal disease (IPD) and hepatitis B virus (HBV), most solid organ transplant (SOT) recipients are without post-transplantation seroprotection against IPD and HBV. We aimed to determine the seroprotection rates and changes in antibody concentrations after booster vaccination against IPD and HBV in SOT recipients without post-transplantation seroprotection after pre-transplantation vaccination. Furthermore, we aimed to identify risk factors associated with non-response to booster vaccination. Methods: In this prospective cohort study, we included adult SOT recipients without post-transplantation seroprotection against IPD who then received the 23-valent pneumococcal polysaccharide vaccine (PPSV23) booster, as well as adult SOT recipients without seroprotection against HBV who then received the Engerix-B® booster after pre-transplantation vaccination. Logistic regression models were used to analyze risk factors for non-response to booster vaccination. Results: We included 50 SOT recipients in analyses of booster vaccination against IPD and 52 SOT recipients in analyses of booster vaccination against HBV. Seroprotection rates were 52% after booster vaccination against IPD and 7.7% after booster vaccination against HBV. The median geometric mean concentration of pneumococcal antibodies increased from 0.54 µg/mL IgG (interquartile range, IQR: 0.35–0.77) to 1.21 µg/mL IgG (IQR: 0.87–1.62) after booster vaccination (p < 0.001). Having pre-transplantation seroprotection against IPD at time of listing was associated with lower odds of non-response to booster vaccination. We were not able to identify risk factors for non-response to HBV booster vaccination. Conclusions: Booster vaccination improved seroprotection against IPD, but not HBV. Further studies are needed to examine optimal vaccination strategies for SOT recipients.
The risk of tuberculosis is increased after solid organ transplantation (SOT) and associated with morbidity and mortality. Pre-transplantation screening and treatment for tuberculosis infection (TBI) is recommended. Aims of this prospective cohort study were determining the prevalence of positive pre-transplantation interferon-gamma release assays (IGRAs), risk factors for a positive result, and describe TBI management. We included SOT candidates from 2020 to 2023 at Rigshospitalet, Denmark with a pre-transplantation IGRA. Data were collected from records and the Danish Microbiology Database. Of 586 patients, 564 (96%) had a pre-transplantation IGRA. Twenty-two (4%) had positive, 537 (95%) negative, and 5 (1%) indeterminate results. Risk factors for a positive IGRA were diabetes (14/480 (3%) without diabetes, 8/84 (10%) with diabetes, aOR 3.07, 95% CI 1.14-7.78), birth in other low-incidence countries (4/24 (17%) vs. 8/463 (2%), aOR 10.14, CI 2.48-35.95) or medium-/high-incidence countries (10/77 (13%), aOR 8.22, CI 3.11-22.43), and alcohol use (aOR 2.75, CI 1.04-7.15). Seventeen patients had TBI; 16 (94%) treated with isoniazid for 6 months, one (6%) with rifampicin for 4 months; treatment discontinued in one case. In conclusion, IGRA screening coverage was high. Positive IGRAs were associated with birth in other low- or medium-/high-incidence countries, diabetes, alcohol use. TBI treatment was well tolerated.
Impaired lung function is more common among liver transplant recipients than the general population, but the pathogenesis is unknown. We investigated whether prior CMV infections are associated with impaired lung function in liver transplant recipients. We invited adult liver transplant recipients from The Danish Comorbidity in Liver Transplant Recipients study (DACOLT) for spirometry and collected data from systematic CMV screening for serostatus and DNAemia. Using linear and logistic regressions adjusted for age, sex, cumulative smoking, and use of inhalation medication, we assessed if prior CMV infections were associated with airflow limitation (FEV 1 /FVC < 0.7 and FEV 1 < 80% of expected) and FEV 1 . Of all eligible liver transplant recipients in Denmark, DACOLT included 600 (79%), and 356 fulfilled the substudy‐specific inclusion criteria. In adjusted models, pretransplant CMV seropositivity was not associated with either airflow limitation (aOR 2.18 [95% CI: 0.71–6.62]) or lower FEV 1 (adjusted β [a β ] = −60 [95% CI: −210 to 80] mL). The same applied to associations between prior CMV DNAemia and airflow limitation (aOR 0.91 [95% CI: 0.35–2.35]) as well as FEV 1 (a β = 30 [95% CI: −120 to 180] mL). This suggests limited clinical impact of CMV infection on posttransplant lung function in liver transplant recipients.
People with HIV (PWH) have a high risk of peripheral artery disease (PAD), and high-sensitivity troponin (hsTnT) and NT-pro B-type natriuretic peptide (NT-proBNP) may be useful biomarkers for PAD in PWH. We assessed associations between hsTnT and NT-proBNP and both prevalent PAD and de novo PAD. Adult PWH were examined at baseline and after 2 years. Inclusion criteria were (1) measurements of hsTnT and NT-proBNP at baseline and (2) ankle brachial index (ABI) at baseline for prevalent PAD and both visits for de novo PAD. PAD was defined as ABI ≤ 0.9. We included 1011 PWH, and 88 (8.7%) had PAD at baseline. Among 802 PWH, 29 (3.6%) had de novo PAD at follow-up. A doubling in hsTnT concentration was associated with prevalent PAD with an OR 1.41 (95% CI: 1.02–1.96, p = 0.04) and 1.40 (95% CI: 0.99–1.98, p = 0.055) in a base model and an adjusted model, respectively. High hsTnT was associated with a risk ratio of 3.39 (95% CI: 1.24–9.27, p = 0.02) for de novo PAD in an unadjusted model and 3.44 (95% CI: 0.98–12.10, p = 0.05) after adjustments. NT-proBNP was not associated with PAD. Thus, hsTnT was associated with higher odds of prevalent PAD and increased risk of de novo PAD.